Interestingly, several studies (Allo et al., 2014; Reske et al., 2021; Wu et al., 2017; Xu and Tang, 2021) have shown that TP53 and ARID1A are frequently mutated across cancer samples but rarely in the same primary tumour. This evidence concerns the gene TP53 and neoplasm.